



## SATELLITE SYMPOSIA



# Bristol-Myers Squibb

SATELLITE SYMPOSIUM SUPPORTED BY BRISTOL-MYERS SQUIBB

16:15 – 18:15

Hall 2

### **TYROSINE KINASE INHIBITORS AND HAEMATOLOGICAL MALIGNANCIES: CURRENT PERSPECTIVES AND FUTURE HORIZONS**

Chair: J Goldman (Hammersmith Hospital, London, United Kingdom)

#### ■ WELCOME AND OUTLINE OF PROGRAMME

Chair

#### ■ CML: WHAT DOES IT MEAN TO BE RESISTANT OR INTOLERANT TO A TKI IN 2009?

J Goldman (Hammersmith Hospital, London, United Kingdom)

#### ■ TRANSLATING CML TRIAL DATA INTO EVERYDAY CLINICAL PRACTICE

D Marin (Hammersmith Hospital, London, United Kingdom)

P le Coutre (Virchow-Klinikum, Berlin, Germany)

J Mayer (University Hospital, Brno, Czech Republic)

#### ■ MANAGEMENT OF IMATINIB RESISTANCE AND INTOLERANCE: THE EVIDENCE

D Marin (Hammersmith Hospital, London, United Kingdom)

#### ■ TREATING THE IMATINIB-RESISTANT CML PATIENT

P le Coutre (Virchow-Klinikum, Berlin, Germany)

#### ■ TREATING THE IMATINIB-INTOLERANT CML PATIENT

J Mayer (University Hospital, Brno, Czech Republic)

#### ■ OTHER HAEMATOLOGICAL MALIGNANCIES: WHERE NEXT FOR TKIs?

G Martinelli (Institute of Hematology and Medical Oncology  
“L.e A. Seragnoli”, Bologna, Italy)

#### ■ PANEL DISCUSSION

Moderated by chair